Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.64 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31291162 | 1.00 | NOTUM (0.64) | NOTUMHSD17B1HSD17B2ALDH1A1HPGD | |
| SCHEMBL31418207 | 0.87 | NOTUM (0.50) | NOTUMHSD17B1HSD17B2KAT6A | |
| SCHEMBL21795694 | 0.86 | NOTUM (0.75) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL31417993 | 0.86 | NOTUM (0.53) | NOTUMHSD17B1HSD17B2CYP3A4CYP2C9 | |
| SCHEMBL31418320 | 0.80 | CHEK1 (0.52) | NOTUMHSD17B1HSD17B2 | |
| SCHEMBL11232897 | 0.79 | NOTUM (0.74) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL31418325 | 0.79 | PIK3CD (0.43) | NOTUMHSD17B1HSD17B2 | |
| SCHEMBL23451501 | 0.78 | NOTUM (1.00) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL3794714 | 0.78 | NOTUM (0.64) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL21776860 | 0.78 | NOTUM (1.00) | NOTUMALDH1A1HPGDMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2025-05-29 | — | — | US | disclosed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| CN-107266505-B | Tetradentate ring metal platinum (II) complex phosphorescence luminescent material | 浙江工业大学 | 2021-11-23 | — | — | CN | disclosed |
| CN-109608506-B | Quadrivalent metal platinum complex containing tetradentate ligand, preparation method, application and device | 浙江工业大学 | 2021-08-06 | — | — | CN | disclosed |
| CN-109476074-A | The manufacturing method of soil resistance film | 夏普株式会社 | 2019-03-15 | — | — | CN | disclosed |
| CN-109475901-A | The manufacturing method of soil resistance film | 夏普株式会社 | 2019-03-15 | — | — | CN | disclosed |
| CN-107266505-A | Tetradentate ring metal platinum (II) complex phosphorescence luminescent material | 浙江工业大学 | 2017-10-20 | — | — | CN | disclosed |
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| WO-2010135360-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009129036-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-6130217-A | ANTITUMOR | PFIZER INC (US) | 2000-10-10 | — | — | US | disclosed |
| WO-1994022846-A1 | COMPOUNDS ENHANCING ANTITUMOR ACTIVITY OF OTHER CYTOTOXIC AGENTS | PFIZER INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-4619929-A | SEDATIVES, HYPOTENSIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1986-10-28 | — | — | US | disclosed |
| EP-0056866-B1 | PHENYLPIPERAZINE DERIVATIVES OF HETERYLPHENOLS AND HETARYLANILINES, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | BASF Aktiengesellschaft (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0034276-B1 | PHENYLPIPERAZINE DERIVATIVES OF 1,3,4-OXADIAZOLYL PHENOLS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1983-11-09 | — | — | EP | disclosed |
| US-4353904-A | TREATMENT OF HYPERTONIA | BASF AKTIENGESELLSCHAFT (DE) | 1982-10-12 | — | — | US | disclosed |
| EP-0056866-A2 | Phenylpiperazine derivatives of heterylphenols and hetarylanilines, their preparation and their pharmaceutical compositions | BASF Aktiengesellschaft (DE) | 1982-08-04 | — | — | EP | disclosed |
| EP-0034276-A2 | Phenylpiperazine derivatives of 1,3,4-oxadiazolyl phenols, their preparation and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | SDHA, GMPS, SDHB | NOTUM 368/4885HSD17B1 2932/4885HSD17B2 2190/4885 |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | NOTUM 4496/4885HSD17B1 2342/4885HSD17B2 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.